In both studies, from a mean baseline body weight of 96.7 kg, and 85.6 kg, respectively, after randomization there were corresponding mean reductions of 1.4 kg, and 1.6 kg in the SYMLIN treatment group compared to mean increases of +0.3 kg, and +0.1 kg in the placebo treatment group
View Full Clinical Case Study #1 This patient manages type 2 diabetes, hypertension, and high cholesterol
The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index
The new normal is that now theres a drug for being overweight that works
Our Priority
Eden Scientific RUO peptides are not evaluated, intended, or approved for diagnostic, therapeutic, clinical, human, or animal applications